News

News

Press Releases

Nov 15, 2021
Tricida Raises $42 Million in Registered Direct Equity Financing
SOUTH SAN FRANCISCO, Calif. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney
Nov 08, 2021
Tricida Announces Third Quarter 2021 Financial Results
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer
Aug 09, 2021
Tricida Announces Second Quarter 2021 Financial Results
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer
May 06, 2021
Tricida Announces First Quarter 2021 Financial Results
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO , May 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed